Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MA › Brockton › NPI 1063431286
Hospital

Brockton Hospital, INC.

Brockton Hospital, INC. was paid $160.74M by Medicaid between Jan 2018 and Dec 2024, across 543 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 9.6% of everything it billed.

33Billing provider infoBROCKTON HOSPITAL, INC.
BROCKTON, MA 02302
33aNPI1063431286assigned 07/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$160.74M
24GClaims3,609,047
24DCodes billed543
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Massachusetts

Rank by total paid#10 of 66
Median peer was paid$29.11M
This provider vs. median5.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M$3.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018594,734$25.63M
2019597,939$22.90M
2020506,954$19.09M
2021644,072$26.51M
2022689,272$31.64M
2023278,356$20.03M
2024incomplete297,720$14.95M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 9.6% 105,443 94,774 $15.48M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 6.8% 90,498 85,290 $10.89M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 6.7% 72,956 65,954 $10.80M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 6.2% 84,277 79,962 $10.04M
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 6.1% 68,587 62,985 $9.82M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 5.9% 58,094 52,943 $9.43M
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 4.1% 106,194 29,465 $6.65M
96361 Intravenous infusion, hydration; each additional hour 4.1% 19,574 15,831 $6.54M
G0378 Hospital observation service, per hour 1.9% 23,509 13,322 $3.12M
G0463 Hospital outpatient clinic visit for assessment and management of a patient 1.8% 108,682 84,379 $2.96M
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 1.8% 15,612 12,821 $2.94M
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete 1.3% 16,122 15,572 $2.16M
531 more codes
74177 Computed tomography, abdomen and pelvis; with contrast material 1.3% 12,486 $2.15M
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.3% 14,228 $2.08M
59025 Fetal non-stress test 1.3% 7,978 $2.02M
99282 Emergency department visit for the evaluation and management, low to moderate severity 1.1% 17,192 $1.75M
70450 Computed tomography, head or brain; without contrast material 1.1% 12,970 $1.74M
76830 Ultrasound, transvaginal <1% 14,338 $1.43M
77063 Screening digital breast tomosynthesis, bilateral <1% 18,383 $1.38M
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 28,090 $1.35M
76801 <1% 9,799 $1.33M
45378 Colonoscopy, flexible; diagnostic, including collection of specimen(s) <1% 1,072 $1.30M
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 1,078 $1.18M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 26,179 $1.11M
97161 <1% 15,346 $1.10M
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up <1% 7,235 $1.09M
99391 Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) <1% 7,406 $1.05M
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 1,422 $1.02M
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 5,494 $994K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 6,407 $969K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 7,893 $959K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 34,680 $929K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 33,616 $895K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 7,299 $850K
76819 Fetal biophysical profile; without non-stress testing <1% 12,464 $810K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 4,444 $805K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 40,954 $805K
71275 Computed tomographic angiography, chest, with contrast material <1% 3,571 $767K
76815 Ultrasound, pregnant uterus, real time with image documentation, limited <1% 5,601 $738K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 10,022 $718K
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) <1% 4,707 $706K
70551 Magnetic resonance imaging, brain; without contrast material <1% 2,503 $689K
93971 <1% 3,045 $662K
71046 Radiologic examination, chest; 2 views <1% 29,999 $657K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 137,266 $654K
93975 <1% 4,772 $650K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 1,704 $647K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 3,807 $644K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 1,992 $609K
76642 <1% 5,732 $607K
81513 <1% 7,350 $604K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) <1% 4,112 $598K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 2,586 $573K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 16,226 $495K
76813 <1% 3,094 $491K
77067 Screening mammography, bilateral, including computer-aided detection <1% 19,361 $484K
96367 <1% 2,873 $473K
76536 <1% 3,729 $457K
73562 <1% 12,205 $441K
76770 <1% 2,846 $441K
84443 Thyroid stimulating hormone (TSH) <1% 47,982 $434K
87428 <1% 7,889 $430K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) <1% 2,774 $418K
83036 Hemoglobin; glycosylated (A1C) <1% 74,429 $412K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 23,274 $396K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 2,109 $373K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 10,501 $353K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 3,501 $339K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 4,417 $337K
99395 Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years <1% 2,577 $323K
94060 <1% 3,434 $316K
80053 Comprehensive metabolic panel <1% 79,396 $307K
80048 Basic metabolic panel (calcium, ionized) <1% 96,526 $304K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 18,901 $298K
12001 <1% 1,774 $298K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 21,050 $296K
73030 <1% 8,964 $293K
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 310 $285K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 30,266 $280K
73630 <1% 8,886 $273K
93017 <1% 2,766 $266K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 2,005 $265K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 4,770 $262K
80050 General health panel <1% 15,070 $255K
73130 <1% 7,536 $247K
82805 <1% 7,866 $247K
99218 <1% 5,274 $245K
73221 <1% 877 $239K
85027 <1% 51,362 $238K
71250 <1% 3,349 $234K
87390 <1% 13,575 $231K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 12,811 $226K
80061 Lipid panel <1% 60,865 $225K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 8,928 $222K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 532 $221K
99396 Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years <1% 1,777 $221K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 56,316 $216K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 7,457 $213K
87481 <1% 7,444 $213K
81025 <1% 37,537 $212K
84484 <1% 26,325 $211K
96375 Therapeutic injection; each additional sequential IV push <1% 25,558 $208K
84702 <1% 16,247 $208K
87086 Culture, bacterial; quantitative colony count, urine <1% 33,257 $207K
10060 <1% 1,280 $203K
95886 <1% 672 $202K
77066 Tomosynthesis, mammo <1% 2,773 $200K
88142 <1% 12,103 $196K
73610 <1% 6,677 $195K
J1756 Injection, iron sucrose, 1 mg <1% 2,470 $194K
99220 <1% 1,379 $191K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 16,122 $185K
73110 <1% 5,013 $179K
87480 <1% 10,630 $172K
87510 <1% 10,627 $171K
87660 <1% 10,620 $171K
90715 <1% 7,468 $169K
83880 <1% 9,961 $164K
90686 <1% 10,967 $162K
73502 <1% 5,190 $154K
86803 <1% 14,639 $153K
99203 Doctor's office visit, new patient (routine) <1% 2,599 $148K
72100 <1% 4,463 $144K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 1,022 $143K
77080 <1% 2,295 $143K
97165 <1% 1,954 $142K
86780 <1% 12,649 $136K
94727 <1% 3,102 $136K
90460 Immunization administration through 18 years of age via any route, first or only component <1% 14,923 $135K
71271 <1% 2,480 $130K
82728 <1% 14,871 $128K
72110 <1% 3,325 $126K
83690 <1% 24,424 $120K
ATP08 <1% 18,291 $119K
83735 <1% 29,512 $119K
76820 <1% 3,215 $116K
76811 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed <1% 1,501 $115K
81001 <1% 49,046 $113K
82607 <1% 12,841 $113K
72125 Computed tomography, cervical spine; without contrast material <1% 4,715 $112K
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 5,026 $108K
74183 <1% 275 $107K
62323 <1% 172 $107K
ATP15 <1% 12,344 $106K
93270 <1% 9,502 $105K
12011 <1% 634 $104K
72141 <1% 446 $102K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 2,593 $97K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 290 $95K
86618 <1% 7,112 $93K
97802 <1% 1,020 $91K
80076 <1% 37,664 $90K
77065 Tomosynthesis, mammo <1% 1,087 $85K
94618 <1% 846 $83K
74018 <1% 2,169 $82K
87340 <1% 9,846 $81K
83970 <1% 3,678 $79K
97803 <1% 900 $75K
94729 <1% 3,177 $75K
85379 <1% 10,810 $72K
73140 <1% 2,140 $69K
G0297 Low dose ct scan (ldct) for lung cancer screening <1% 775 $67K
85610 <1% 27,703 $67K
93970 <1% 333 $66K
82746 <1% 7,818 $66K
73080 <1% 2,096 $65K
88342 <1% 2,222 $65K
86850 <1% 10,287 $64K
87186 <1% 10,683 $64K
87081 <1% 11,414 $64K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 598 $64K
29125 <1% 683 $64K
87653 <1% 2,121 $63K
83605 <1% 8,692 $63K
82570 <1% 19,695 $61K
83540 <1% 14,874 $61K
ATP14 <1% 10,869 $59K
84439 <1% 10,466 $58K
12002 <1% 379 $58K
87631 <1% 521 $57K
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units <1% 3,435 $55K
83550 <1% 10,051 $55K
81003 <1% 33,231 $54K
86762 <1% 4,363 $54K
82043 <1% 17,491 $54K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 7,165 $53K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 957 $53K
76882 <1% 484 $52K
96415 <1% 343 $51K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 153 $51K
83721 <1% 9,897 $50K
80074 <1% 1,310 $49K
86787 <1% 4,151 $49K
84146 <1% 3,298 $48K
99215 Doctor's office visit, returning patient (complex) <1% 213 $48K
72050 <1% 1,033 $47K
86003 <1% 1,026 $47K
82784 <1% 6,738 $46K
99217 <1% 835 $46K
73564 <1% 732 $46K
77002 <1% 247 $44K
71045 Radiologic examination, chest; single view <1% 10,693 $44K
87420 <1% 4,007 $43K
87040 <1% 4,423 $43K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 4,591 $42K
70491 <1% 313 $40K
J2469 Injection, palonosetron hcl, 25 mcg <1% 405 $39K
97162 <1% 533 $39K
86334 <1% 3,160 $38K
86140 <1% 10,669 $37K
87522 Neg quan hep c or qual rna <1% 1,043 $37K
90677 <1% 858 $37K
72040 <1% 700 $37K
S9485 Crisis intervention mental health services, per diem <1% 94 $37K
86706 <1% 4,545 $36K
86704 <1% 4,012 $35K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 436 $35K
84100 <1% 21,185 $34K
70486 <1% 779 $34K
83001 <1% 2,154 $33K
84145 <1% 5,104 $33K
88304 <1% 2,366 $33K
86696 <1% 1,297 $33K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 664 $32K
84403 <1% 1,665 $31K
90750 <1% 555 $31K
93296 <1% 1,086 $31K
86900 <1% 12,052 $31K
83021 <1% 1,949 $31K
76886 <1% 209 $31K
87088 <1% 5,445 $31K
99204 Doctor's office visit, new patient (more involved) <1% 315 $30K
84703 <1% 4,906 $29K
92551 <1% 289 $29K
Q3014 Telehealth originating site facility fee <1% 12,457 $29K
82962 <1% 13,915 $28K
86901 <1% 11,991 $28K
G0279 Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) <1% 1,881 $28K
82670 <1% 1,103 $28K
84425 <1% 1,714 $27K
J1650 Injection, enoxaparin sodium, 10 mg <1% 3,798 $27K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 704 $27K
85652 <1% 14,417 $26K
96376 <1% 8,276 $26K
87070 <1% 4,233 $25K
86235 <1% 674 $25K
85730 <1% 6,357 $25K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) <1% 713 $25K
84165 <1% 3,339 $24K
86038 <1% 2,769 $24K
83516 <1% 1,813 $23K
86708 <1% 2,426 $23K
86480 <1% 516 $23K
ATP17 <1% 8,491 $22K
73590 <1% 1,256 $22K
97035 <1% 322 $22K
86695 <1% 1,299 $22K
ATP09 <1% 3,382 $22K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 11,627 $22K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 23,316 $22K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 16,932 $22K
87147 <1% 5,040 $22K
87077 <1% 4,671 $21K
84402 <1% 921 $20K
J2704 Injection, propofol, 10 mg <1% 17,874 $20K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 7,032 $20K
84480 <1% 2,107 $19K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 22,368 $19K
36415 Collection of venous blood by venipuncture <1% 48,431 $19K
72197 <1% 48 $18K
G2066 Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results <1% 841 $18K
90472 Immunization administration, each additional vaccine (list separately) <1% 1,936 $18K
99173 <1% 431 $18K
G0008 Administration of influenza virus vaccine <1% 4,259 $17K
80179 <1% 2,926 $17K
ATP16 <1% 1,935 $17K
0240U <1% 412 $17K
90670 <1% 1,782 $16K
99381 <1% 103 $16K
J1439 Injection, ferric carboxymaltose, 1 mg <1% 17 $16K
76870 <1% 166 $16K
72072 <1% 442 $16K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 5,989 $15K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 20,666 $15K
83002 <1% 862 $15K
82950 <1% 3,274 $14K
90662 <1% 1,461 $14K
93299 <1% 466 $14K
80143 <1% 2,789 $14K
82565 <1% 9,521 $13K
80171 <1% 1,489 $13K
87205 <1% 4,204 $13K
84466 <1% 1,182 $13K
87338 <1% 1,144 $13K
70496 <1% 115 $13K
J0690 Injection, cefazolin sodium, 500 mg <1% 5,535 $12K
19083 <1% 12 $12K
J0171 Injection, adrenalin, epinephrine, 0.1 mg <1% 935 $11K
73090 <1% 607 $11K
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 2,912 $11K
85045 <1% 4,234 $11K
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 7,366 $10K
88300 <1% 288 $10K
84460 <1% 7,713 $10K
84550 <1% 5,253 $10K
20610 <1% 45 $9K
83883 <1% 1,236 $9K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 327 $9K
84153 <1% 1,130 $9K
82550 <1% 5,296 $9K
82747 <1% 609 $9K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 171 $9K
90746 <1% 314 $9K
71101 <1% 385 $9K
86709 <1% 911 $9K
90651 <1% 866 $9K
90732 <1% 361 $9K
J1030 Injection, methylprednisolone acetate, 40 mg <1% 3,638 $9K
90656 <1% 787 $9K
83010 <1% 1,027 $9K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 9,836 $8K
84450 <1% 7,033 $8K
ATP02 <1% 2,496 $8K
86765 <1% 626 $8K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 282 $8K
84520 <1% 7,205 $8K
92552 <1% 50 $8K
87899 <1% 734 $8K
86735 <1% 598 $8K
76942 <1% 27 $7K
90620 <1% 446 $7K
97014 <1% 78 $7K
83615 <1% 3,790 $7K
86160 <1% 532 $7K
86666 <1% 507 $7K
84156 <1% 2,368 $7K
88313 <1% 393 $7K
84132 <1% 4,616 $7K
87046 <1% 841 $6K
86317 <1% 372 $6K
74019 <1% 558 $6K
95909 <1% 35 $6K
80164 <1% 1,438 $6K
84255 <1% 245 $6K
84155 <1% 2,990 $6K
85018 <1% 2,845 $5K
82247 <1% 2,788 $5K
82150 <1% 998 $5K
86617 <1% 351 $5K
82465 <1% 1,136 $5K
J2785 Injection, regadenoson, 0.1 mg <1% 268 $5K
ATP03 <1% 4,868 $5K
86430 <1% 1,018 $5K
90694 <1% 514 $5K
84144 <1% 241 $4K
82525 <1% 421 $4K
86376 <1% 343 $4K
86039 <1% 500 $4K
ATP05 <1% 856 $4K
A9500 Technetium tc-99m sestamibi, diagnostic, per study dose <1% 1,252 $4K
87045 <1% 470 $4K
82172 <1% 267 $4K
84630 <1% 395 $4K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 23 $4K
85014 <1% 2,227 $4K
82947 <1% 1,960 $4K
88312 <1% 54 $4K
82785 <1% 271 $4K
20552 <1% 13 $4K
90716 <1% 446 $4K
84295 <1% 1,722 $4K
82627 <1% 172 $4K
87015 <1% 745 $4K
93225 <1% 40 $4K
82274 <1% 228 $3K
J1644 Injection, heparin sodium, per 1000 units <1% 3,284 $3K
93226 <1% 38 $3K
90707 <1% 494 $3K
J2060 Injection, lorazepam, 2 mg <1% 5,685 $3K
86255 <1% 107 $3K
J2270 Injection, morphine sulfate, up to 10 mg <1% 7,340 $3K
86753 <1% 286 $3K
86200 <1% 215 $3K
73560 <1% 55 $3K
ATP07 <1% 741 $3K
86580 <1% 249 $2K
97760 <1% 48 $2K
90653 <1% 300 $2K
82140 <1% 452 $2K
82310 <1% 968 $2K
87625 <1% 68 $2K
0071A <1% 51 $2K
82040 <1% 1,003 $2K
73552 <1% 65 $2K
99224 <1% 74 $2K
97018 <1% 29 $2K
94760 <1% 5,227 $2K
82652 <1% 63 $2K
88311 <1% 70 $2K
87329 <1% 200 $2K
85007 <1% 985 $2K
90688 <1% 51 $2K
0072A <1% 40 $2K
93298 <1% 84 $2K
87328 <1% 186 $2K
72131 <1% 41 $2K
82977 <1% 647 $2K
82668 <1% 147 $2K
99188 <1% 46 $2K
82378 <1% 115 $2K
84481 <1% 102 $1K
72081 <1% 27 $1K
J3411 Injection, thiamine hcl, 100 mg <1% 25 $1K
87181 <1% 581 $1K
83520 <1% 127 $1K
86308 <1% 307 $1K
82533 <1% 98 $1K
86225 <1% 128 $1K
G0108 Diabetes outpatient self-management training services, individual, per 30 minutes <1% 14 $1K
82077 <1% 271 $1K
95913 <1% 12 $1K
87493 <1% 55 $1K
83986 <1% 641 $1K
ATP18 <1% 670 $1K
J1040 Injection, methylprednisolone acetate, 80 mg <1% 278 $1K
99234 <1% 12 $1K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 2,142 $1K
G0009 Administration of pneumococcal vaccine <1% 513 $984.24
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 6,143 $977.22
ATP10 <1% 435 $974.06
Q9960 High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml <1% 1,297 $950.16
92083 <1% 28 $939.49
69209 <1% 71 $939.26
82951 <1% 77 $926.93
73060 <1% 44 $923.09
83525 <1% 81 $912.65
92133 <1% 25 $871.91
ATP11 <1% 412 $763.28
86880 <1% 216 $721.89
74220 <1% 12 $695.18
0001A <1% 15 $688.20
83498 <1% 24 $672.24
82248 <1% 1,515 $656.27
93246 <1% 238 $650.05
80051 <1% 209 $617.24
ATP13 <1% 250 $598.95
84311 <1% 413 $538.80
J1170 Injection, hydromorphone, up to 4 mg <1% 266 $502.41
73523 <1% 12 $502.41
86431 <1% 92 $494.14
80178 <1% 196 $483.16
86769 <1% 12 $469.90
J3475 Injection, magnesium sulfate, per 500 mg <1% 924 $466.53
74174 <1% 12 $462.72
82340 <1% 106 $453.68
93242 <1% 206 $447.19
90734 <1% 134 $423.61
70498 <1% 91 $417.36
90461 <1% 219 $410.95
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 685 $392.85
87184 <1% 123 $384.47
86800 <1% 27 $381.36
ATP04 <1% 113 $362.90
G0433 Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening <1% 616 $350.61
87255 <1% 12 $347.79
80069 <1% 110 $325.47
82330 <1% 31 $319.02
ATP23 <1% 32 $314.73
70360 <1% 12 $302.52
90696 <1% 245 $298.00
J1630 Injection, haloperidol, up to 5 mg <1% 1,137 $286.23
J2710 Injection, neostigmine methylsulfate, up to 0.5 mg <1% 535 $278.23
88173 <1% 13 $261.56
87425 <1% 22 $240.68
90633 <1% 879 $210.71
90632 <1% 13 $203.60
76376 <1% 1,639 $202.32
87324 <1% 33 $192.42
80177 <1% 46 $191.38
83718 <1% 28 $187.96
S9083 Global fee urgent care centers <1% 292 $179.72
81050 <1% 65 $175.98
96417 <1% 34 $172.54
J3370 Injection, vancomycin hcl, 500 mg <1% 1,164 $169.27
ATP06 <1% 69 $105.04
82948 <1% 23 $102.70
88112 <1% 18 $79.38
80156 <1% 13 $75.15
85049 <1% 12 $51.79
82952 <1% 14 $50.12
J0713 Injection, ceftazidime, per 500 mg <1% 173 $48.15
84075 <1% 13 $43.90
15853 <1% 14 $39.24
82272 <1% 14 $38.56
J2550 Injection, promethazine hcl, up to 50 mg <1% 153 $27.02
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care <1% 77 $27.00
82270 <1% 13 $26.88
90710 <1% 76 $19.06
J2795 Injection, ropivacaine hydrochloride, 1 mg <1% 68 $18.13
90713 <1% 14 $14.16
J1815 Injection, insulin, per 5 units <1% 59 $8.33
C9113 Injection, pantoprazole sodium, per vial <1% 2,185 $8.15
96368 0% 33 $0.00
C1769 Guide wire 0% 225 $0.00
90680 0% 41 $0.00
G8980 Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting 0% 204 $0.00
90697 0% 336 $0.00
90723 0% 650 $0.00
G8988 Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 45 $0.00
J0330 Injection, succinylcholine chloride, up to 20 mg 0% 93 $0.00
80320 0% 115 $0.00
94761 0% 393 $0.00
J0515 Injection, benztropine mesylate, per 1 mg 0% 113 $0.00
A9585 Injection, gadobutrol, 0.1 ml 0% 23 $0.00
A4648 Tissue marker, implantable, any type, each 0% 12 $0.00
90744 0% 16 $0.00
84478 0% 21 $0.00
J1010 Injection, methylprednisolone acetate, 1 mg 0% 85 $0.00
J3360 Injection, diazepam, up to 5 mg 0% 159 $0.00
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg 0% 82 $0.00
80329 0% 65 $0.00
J2470 Injection, pantoprazole sodium, 40 mg 0% 15 $0.00
91307 0% 21 $0.00
J1790 Injection, droperidol, up to 5 mg 0% 15 $0.00
G8987 Self care functional limitation, current status, at therapy episode outset and at reporting intervals 0% 16 $0.00
90648 0% 1,041 $0.00
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals 0% 511 $0.00
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program 0% 3,616 $0.00
99053 0% 15 $0.00
99221 0% 28 $0.00
90700 0% 335 $0.00
G8985 Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 76 $0.00
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 662 $0.00
90681 0% 310 $0.00
Q0177 Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen 0% 70 $0.00
90649 0% 13 $0.00
90685 0% 32 $0.00
J0295 Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm 0% 199 $0.00
J0744 Injection, ciprofloxacin for intravenous infusion, 200 mg 0% 21 $0.00
G8984 Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals 0% 29 $0.00
J1953 Injection, levetiracetam, 10 mg 0% 20 $0.00
Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml 0% 14 $0.00
87563 0% 18 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHAFFEY, ROBERT (CEO)